John H Strickler
Academic and Community Cancer Research United · Duke University - Duke Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John H Strickler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05356897 · Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyAcademic and Community Cancer Research United · withdrawn · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma · principal investigator
- Ph2NCT03992456 · Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerAcademic and Community Cancer Research United · unknown · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma · principal investigator
- N/ANCT03765736 · Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE TrialAcademic and Community Cancer Research United · terminated · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8 · principal investigator
- Ph2NCT03592641 · Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerNational Cancer Institute (NCI) · terminated · Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma · principal investigator
- Ph2NCT03043313 · Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerSeagen Inc. · completed · Metastatic Colorectal Adenocarcinoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Precision Cancer Med (PCM) & InvestigationP30CA014236 · NCI · DUKE UNIVERSITY · fiscal years 2025 to 2026 · $223,070 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT03592641
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:07 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.N Engl J Med · 2023466 citationsRCR 40.2
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.Lancet Oncol · 2022286 citationsRCR 17.0
- 220 citationsRCR 18.8
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.Lancet Oncol · 2024144 citationsRCR 16.4
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.J Clin Oncol · 2018125 citationsRCR 3.8
- First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.Cancer Immunol Immunother · 2023122 citationsRCR 9.8
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.J Clin Oncol · 2023105 citationsRCR 8.9
- Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.Clin Cancer Res · 202172 citationsRCR 3.7
- A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.Clin Cancer Res · 202262 citationsRCR 3.5